Wire · opportunities
Kelun-Biotech partner reports positive asthma Phase 2 trial results
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
Kelun-Biotech's partner Windward Bio reported positive interim Phase 2 results for SKB378/WIN378, a novel ultra-long-acting monoclonal antibody targeting TSLP in asthma patients, showing significant improvements in lung function and inflammation markers with good safety and potential for twice-yearly dosing.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.
◆ ◆ The Wire takeaway
Your asthma drug has shown clear benefits and safety at an extended dosing interval, opening direct access to patients needing less frequent treatment. Expect trial advances to quickly shape Phase 3 design and investor interest in your lung health innovations.
◆ Coverage
1 source · 10 Sep 2026
◆ Related on Wire
◆ Topics